



October 28, 2021

PRESS RELEASE FOR IMMEDIATE USE

Dechra is pleased to announce the acquisition of Sucromate™ Equine (deslorelin acetate) sterile suspension from Thorn Bioscience L.L.C. This acquisition expands Dechra's equine portfolio in the reproductive category.

Mike Eldred, President of Dechra North America, stated, "Sucromate Equine is a sterile, synthetic gonadotropin-releasing hormone (GnRH) analog suspension that veterinarians have used and relied on for their breeding operations. Sucromate Equine expands Dechra's reproductive portfolio and complements our existing product offering."

Sucromate Equine (deslorelin acetate) sterile suspension should be used exclusively by veterinarians.

The product is now available for veterinarians to purchase through select veterinary distributors.

Contact:

Mike Eldred
President, North American Operations
Dechra Veterinary Products
Mike.Eldred@Dechra.com

Doug Hubert
Vice President, Sales and Marketing
Dechra Veterinary Products
Doug.Hubert@Dechra.com

About Dechra

Dechra Veterinary Products' equine portfolio includes Osphos® (clodronate injection), Orthokine® vet irap 10 and 60, and Osteokine® (PRP). Dechra also offers Equidone® Gel (domperidone), the Vetivex® line of parenteral fluids, Phycox® EQ joint health supplements, and a comprehensive line of topical dermatologic products. The recent additions of ProVet™ APC (Autologous Platelet Concentrate) system, Rompun® (xylazine injection), Butorphanol Tartrate Injection, and Zimeta® (dipyron injection) further expand Dechra's equine offerings.